275例吸附无细胞百白破疫苗疑似预防接种异常反应病例的流行病学分析  

Study on the Epidemiological Characteristics of 275 DTaP Vaccine AEFI Cases

作　　者：彭时辉[1] 文海蓉[1] 许波[1] 张艳霞[1] 

机构地区：[1]江西省南昌市疾病预防控制中心免疫规划所,江西南昌330038

出　　处：《现代预防医学》2016年第18期3413-3415,3456,共4页Modern Preventive Medicine

摘　　要：目的了解南昌市使用的吸附无细胞百白破疫苗的安全性。方法分析南昌市2010-2015年通过全国疑似预防接种异常反应信息管理系统收集到的与接种百白破疫苗有关的AEFI(疑似预防接种异常反应)数据。结果南昌市2010-2015年共报告与接种百白破疫苗有关的AEFI病例275例,报告发生率为15.90/10万,男女性别比为2.31∶1,多发生在第4剂次和接种后≤1 d。不良反应中,一般反应233例,报告发生率为15.90/10万,以发热、红肿、硬结为主,预防接种异常反应40例,报告发生率为2.31/10万,过敏性皮疹最多,有24例,报告发生率为1.39/10万。结论南昌市使用的百白破疫苗不良反应报告发生率在预期发生范围内,具有较好的安全性。Objective The study aimed to assess the safety of DTaP used in Nanchang District. Methods Data on adverse events following immunization （AEFI） with DTaP from the National AEFI Information Management System in Nanchang District between 2010 and 2015 were analyzed. Results A total of 275 AEFI cases related to DTaP were reported in Nanchang District between 2010 and 2015, with an incidence of 15.90/100000. The ratio of male： female was 2.31：1. Vaccine reactions often occurred in the fourth dose and within 1 day after vaccination. In all vaccine reactions, the cases included 233 cases of common vaccine reactions, with an incidence of 15.90/100000. The main symptoms of common vaccine reactions were fever, local swelling and indurations. The cases included 40 cases of adverse reactions, with an incidence of 2.31/100000. Allergic eruption was the most common adverse reactions, with 24 cases reported and an incidence of 1.39/100000. Conclusion The estimated incidence of adverse reactions following DTaP immunization in Nanchang District was within the safety range, confirming the safety of the vaccine.

关 键 词：百白破疫苗 疑似预防接种异常反应 分析 

分 类 号：R181.2[医药卫生—流行病学] R186[医药卫生—公共卫生与预防医学]